You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News items for the week of April 12, 2021.
PanCAN has invested $25 million in the study, which will screen blood samples from new-onset diabetes patients for biomarkers associated with pancreatic cancer.
The company will use the funds to accelerate the clinical development and commercialization of its minimal residual disease detection C2-Intelligence Platform.
The trial will identify patients using NGS and an IHC assay, which Ideaya and Ventana codeveloped to confirm MTAP protein levels.
The French cancer center will use OncoDNA's blood-based next-generation sequencing test, OncoFollow, in its ongoing SCANDARE study.
Flagship will use its RNAscope assay and image analysis to screen advanced gastric and gastroesophageal cancer patients for elevated DKK1 RNA expression.
The team will use NanoView's ExoView platform to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing therapy.
The combined company is expected to receive $353 million in gross proceeds, which will help advance several of Tango's precision oncology drug candidates.
The approval from China's National Medical Products Administration expands access to the drug in a country with a significant lung cancer burden.
The company's pipeline includes a KIT inhibitor that will move into clinical studies this year and an EGFR inhibitor in preclinical studies.